Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

DBDivaya BhutaniYBYevgeniy BrailovskyRCRajshekhar Chakraborty

Discussion

Loading...

Member takes

Overview

Prospective trial shows hematologic responses in systemic AL amyloidosis with daratumumab-based therapies, suggesting improved outcomes for high-risk patients.

Key Points

  • Overall survival at 1 year for patients treated with daratumumab was 45%, indicating a modest benefit compared to historical data.
  • A total of 36 patients with Mayo stage IIIb systemic AL amyloidosis were treated with daratumumab-based regimens, demonstrating a 27.5% heme-CR rate.
  • Hematologic responses were evaluated, highlighting the significance of renal replacement therapy in this patient population with complex cardiac involvement.
  • NYHA class significantly predicted overall survival, emphasizing the need for tailored clinical strategies in treating advanced systemic AL amyloidosis.

Cite This Study

Bhutani et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e02ehttps://doi.org/10.1182/blood-2025-5740
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab-based regimens in newly diagnosed mayo 2004 stage 3b AL amyloidosis: A systematic review2025
  2. 2Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab2025
  3. 3Real-world outcomes of standard and modified daratumumab-based therapy in AL amyloidosis: A cohort study from a multidisciplinary program in south India2025
  4. 4Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)2025
  5. 5Daratumumab in AL amyloidosis: survival, cardiac CR, and beyond2026